Medicine for treating irritable bowel syndrome and applications thereof

A technology for irritable bowel syndrome and drugs, applied in the field of medicine, can solve problems such as the reduction of active ingredients

Active Publication Date: 2014-06-04
3 Cites 1 Cited by

AI-Extracted Technical Summary

Problems solved by technology

[0003] Traditional Chinese medicine is often produced by decocting decoctions, oral tablets, capsules, etc....
View more


The invention relates to a medicine for treating irritable bowel syndrome. The medicine is prepared from the following medicinal raw materials in parts by weight: 16 parts of ceriops tagal, 12 parts of levisticum, 13 parts of tartar poplar resin, 12 parts of fathead tree, 15 parts of farges decaisnea root, 10 parts of tall rattlesnake plantain herb, 10 parts of cowherb seed, 11 parts of radix cyathulae, 10 parts of cortex acanthopanax radicis, 10 parts of radix dipsaci, 11 parts of jujube, 11 parts of vicia hirsuta, 8 parts of fructus piperis longi, 9 parts of fructus lycii, 8 parts of semen astragali complanati, 8 parts of pilea muscosa, 7 parts of rhizoma gastrodiae, 8 parts of radix triplostegiae glanduliferae, 9 parts of fructus xanthii, 8 parts of flos magnoliae, 7 parts of herba schizonepetae, 8 parts of corn stigma, 3 parts of radix rehmanniae, 2 parts of radix curcumae, 1 part of semen sesami nigri, 5 parts of flos carthami, 2 parts of mung bean, 3 parts of cortex eucommiae, 2 parts of jerusalem artichoke, 3 parts of fructus alpiniae oxyphyllae, 1 part of semen cuscutae, 2 parts of star-sky alternanthera, 3 parts of radix polygalae and 2 parts of calamus margaritae hance. The medicine for treating irritable bowel syndrome is reasonable in composition, and has extract curative effect and is safe and convenient, free of toxic and side effects, and low in price.

Application Domain

Digestive systemPlant ingredients

Technology Topic

CarthamusVicia hirsuta +12


  • Experimental program(1)

Example Embodiment

[0017] Experimental example
[0018] Diagnostic criteria:
[0019] 1. Abdominal pain, bloating, diarrhea and constipation are the main symptoms, accompanied by systemic neurological symptoms; 2. The general condition is good, no weight loss and fever, and the systemic physical examination only finds abdominal tenderness; 3. Repeated stool routine and culture ( At least 3 times) were negative, and the stool occult blood test was negative; 4. Fiber colonoscopy showed that the patient had hyperkinesis, no obvious mucus abnormalities, and histological examination was basically normal; 5. Blood and urine routines were normal, and the erythrocyte sedimentation rate was normal; 6. No dysentery, History of schistosomiasis, experimental treatment is ineffective.
[0020] 0.05), comparable.
[0021] The treatment group was treated with the patch prepared in the example, and one patch was attached to the patient's belly button twice a day. Continuous treatment for 20 days.
[0022] In the control group, Imodium (purchased from Xi'an Janssen Pharmaceutical Co., Ltd.) was taken orally, 2 mg each time, 3 times a day for 20 consecutive days.
[0023] Efficacy criteria
[0024] Cure: The clinical symptoms disappeared, bowel movements were performed once a day, stool characteristics were normal, and there was no recurrence after follow-up for more than half a year. Significant effect: Abdominal pain or abdominal discomfort disappears during defecation, diarrhea is less than 3 times a day, and stool characteristics are significantly improved. Effective: Abdominal pain and abdominal discomfort disappeared during defecation, and the frequency of defecation and stool characteristics were not significantly improved. Ineffective: No obvious change in symptoms before and after treatment.
[0025] result
[0026] After treatment, the treatment results of the two groups are shown in the following table:
[0027] Group


no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products